GleamWall
中文EN

ZNTL Zentalis Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1725160 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.8%
TTM net income YoY16.7%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-615.2%
Net margin-555.8%
FCF margin-498.8%
EBITDA margin-611.8%

Returns

ROE-49.2%
ROA-38.4%
ROIC (approx.)-49.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets22.7%
Debt / equity0.00x
Current ratio7.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$67.42M
R&D expense$107.30M$167.77M
SG&A expense$37.72M$87.11M
Operating income-$152.81M-$191.19M
Pretax income-$136.62M-$165.69M
Income tax$442,000$177,000
Net income-$137.06M-$165.84M
EBITDA-$152.07M-$189.91M
EPS (basic)-1.91-2.33
EPS (diluted)-1.91-2.33
Weighted avg. shares (diluted)71.87M71.08M
Balance sheet
Cash & equivalents$35.99M$36.53M
Short-term investments$209.90M$318.01M
Receivables$0$5.00M
Current assets$253.19M$386.07M
PP&E, net$2.77M$4.70M
Goodwill—$0
Total assets$288.97M$430.34M
Current liabilities$36.56M$52.73M
Total liabilities$72.76M$93.15M
Shareholders' equity$216.20M$337.19M
Shares outstanding69.09M71.28M
Cash flow statement
Operating cash flow-$125.25M-$170.86M
Capital expenditure$0$221,000
Free cash flow-$125.25M-$171.08M
Investing cash flow$131.62M$176.56M
Financing cash flow-$4.28M$108,000
Depreciation & amortization$739,000$1.29M
Stock-based compensation$20.72M$67.27M
Share buybacks$9.98M$0

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.